NCT05347212 2026-04-15
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
106 trialsNCT06532279 2026-04-03
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
Phase 2 Recruiting
NCT07281768 2026-03-20
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Not yet recruiting
NCT06205836 2026-03-17
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06806930 2026-03-03
Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
George Washington University
Phase 2 Recruiting
NCT02574728 2026-03-02
AflacST1502
Emory University
Phase 2 Active not recruiting
NCT05063916 2026-02-27
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05014776 2026-02-24
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT07408635 2026-02-13
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT03993353 2026-02-12
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
Phase 2 Completed
NCT06636734 2026-02-11
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Emory University
Phase 2 Recruiting
NCT06001658 2025-12-03
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06941857 2025-12-03
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT07246668 2025-11-24
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Yonsei University
Phase 2 Recruiting
NCT05977998 2025-11-19
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05541016 2025-11-04
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Mayo Clinic
Phase 2 Recruiting
NCT06445114 2025-11-04
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT02994069 2025-10-14
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
University of Kentucky
Phase 2 Active not recruiting
NCT07145801 2025-10-07
TARE
Thomas Jefferson University
Phase 2 Recruiting
NCT00210171 2025-09-10
BIB 01
Institut Bergonié
Phase 2 Withdrawn
NCT05263245 2025-09-03
Skippy 1
Leiden University Medical Center
Phase 2 Completed
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT03795610 2025-07-25
IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
University of California, San Diego
Phase 2 Completed
NCT01125449 2025-05-18
Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease
Situs Cancer Research Center
Phase 2 Withdrawn
NCT06969534 2025-05-15
Safety and Efficacy of Pucotenlimab in pLECC
Sun Yat-sen University
Phase 2 Recruiting
NCT06813079 2025-02-18
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT04162873 2025-02-12
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
University of Utah
Phase 2 Terminated
NCT03708224 2025-01-28
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
University of California, San Francisco
Phase 2 Recruiting
NCT05917158 2025-01-22
1
Jinling Hospital, China
Phase 2 Recruiting
NCT04791228 2025-01-01
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Children's National Research Institute
Phase 2 Withdrawn
NCT06551896 2024-08-13
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT03190265 2024-08-07
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04807166 2024-07-03
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Active not recruiting
NCT04541355 2024-06-28
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
University of California, San Francisco
Phase 2 Completed
NCT03331601 2024-04-24
Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients
Universitair Ziekenhuis Brussel
Phase 2 Recruiting
NCT03396471 2024-04-18
Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
Hoosier Cancer Research Network
Phase 2 Terminated
NCT06134193 2023-11-18
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT05494060 2023-11-07
EXPLORING
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06112041 2023-11-01
The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
Second Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT03546166 2023-07-21
PICABAS
Centre Hospitalier Universitaire de Nice
Phase 2 Completed
NCT04962958 2023-06-22
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05913661 2023-06-22
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT00176267 2023-06-01
Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer
University of Kentucky
Phase 2 Completed
NCT00176254 2023-05-16
Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer
University of Kentucky
Phase 2 Completed
NCT05541146 2023-03-23
Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis
Instituto do Cancer do Estado de São Paulo
Phase 2 Unknown
NCT01253161 2023-03-06
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02440425 2022-10-07
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02920476 2022-06-23
UF-STO-LUNG-003
University of Florida
Phase 2 Completed
NCT05265793 2022-03-04
Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
Fudan University
Phase 2 Unknown
NCT05115500 2021-11-10
ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)
Second Affiliated Hospital of Soochow University
Phase 2 Unknown